Clinical trial
A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
NCT03270176 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
- Lead sponsor
- Debiopharm International SA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 10, 2017
- Completion date
- March 22, 2022
- Enrollment
- 54 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.